 DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt Nasdaq: AMYT, AIM: AMYT, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces the completion of the rolling submission of a New Drug Application NDA to the U.S. Food and Drugs Administration FDA for Oleogel-S10 for the potential treatment of cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa EB. EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. 